P512 Early proactive therapeutic drug monitoring with ustekinumab therapy in paediatric Crohn's Disease

A Ricciuto,H McKay,J deBruyn,E Crowley,P Church,H Huynh,A Otley,A Shaikh,W El-Matary,E Wine,T Walters,A Griffiths

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0642

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background In the treatment of paediatric Crohn’s disease (CD), the youngest (lightest) children have historically been underdosed by standard weight-based dosing. Paediatric data on optimal dosing and drug levels are sparse. We aimed to examine real-world post-induction pharmacokinetic and effectiveness in a prospective multicentre paediatric CD cohort. Methods Luminal CD patients 2-17 years old in the Canadian Children IBD Network were eligible if they received UST IV and had a serum UST level measured proactively at week (wk) 8. Wk8 and subsequent UST levels were compared between children <40 and ≥40 kg (Mann-Whitney-U), dosed in accordance with an ongoing phase 3 paediatric trial. We calculated a “dose to exposure ratio” by dividing induction dose by wk8 level. Clinical remission was defined as wPCDAI <12.5 while still on UST. We used ROC curves to define optimal (Youden index) wk8 levels associated with wk16 remission and subsequent UST continuation. Continuous measures are reported as median (IQR). Results 44 children were eligible from April 2017-April 2023 (70% M; age 13.1 (10.8-15.5) y; disease duration 0.3 (0.08-1.3) y; weight 44.7 (30.4-55.0) kg, 12 <40kg; 75% bio-naïve; L1 18%, L2 23%, L3 52%; SES-CD at diagnosis 17 (11-21)). At UST start, wPCDAI was 27.5 (10-52.5) and albumin was similar between weight groups (p=0.3). Median follow-up was 10 (7-13) months. 68% received 260 mg IV loading dose, 16% 390 mg. All received 90 mg SC q8 weekly maintenance. Induction doses in mg/kg and mg/m2 were significantly higher in children <40 kg (Table 1). Despite this, wk8 levels were similar between weight groups, with the same pattern at other times. The dose (mg/kg) to exposure ratio was 1.45x higher in children <40kg, indicating they received more drug per unit increase in serum UST level relative to heavier children. Interval shortening to q4wk occurred in 7 prior to wk16, and in 16 (36%) by 6 months. By wk16, 56% of patients with available wPCDAI were in clinical remission and 60% at 1 year. Overall, 7 (16%) ceased UST. Wk8 UST levels were numerically higher in those who achieved wk16 clinical remission (7.4 (6.2-10.2) vs. 5.5 (2.6-7.1), p=0.094), and numerically lower in those who ceased UST (4.9 (2.6-6.9) vs. 7.3 (5.4-10.7), p=0.087). Based on ROC, the optimal wk8 UST level associated with wk16 clinical remission was 5.8 (AUC 0.68, sensitivity 78%, specificity 57%). The optimal level associated with UST continuation was 7.9 (AUC 0.73, sensitivity 43%, specificity 100%, Figure 1). Conclusion Paediatric CD patients weighing <40kg required higher UST doses to achieve comparable drug exposure to those ≥40kg. Positive clinical outcomes were associated with higher UST levels (with optimal cut-offs 6-8). Figure 1

gastroenterology & hepatology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: in the treatment of paediatric Crohn's disease (CD), do children with lower body weight (especially those with a body weight of less than 40 kg) need a higher dose of ustekinumab (UST) to achieve a drug exposure level comparable to that of children with higher body weight when using ustekinumab (UST), and explore the impact of early active therapeutic drug monitoring (TDM) on clinical efficacy.

### Specific problems include:
1. **Dose adjustment**: Do children with lower body weight need a higher dose of ustekinumab to achieve the same blood drug concentration as children with higher body weight?
2. **Relationship between drug exposure and efficacy**: What is the relationship between the blood drug concentration of ustekinumab and clinical remission? Is there an optimal blood drug concentration range that can predict clinical remission at week 16 and the continuity of subsequent treatment?
3. **Effectiveness in practical application**: In the real world, can early active drug monitoring improve the effectiveness of ustekinumab treatment?

### Research background:
- In the treatment of paediatric Crohn's disease, the traditional standard dose calculated according to body weight may lead to insufficient medication in children with lower body weight.
- The data on the optimal dose and drug level in paediatric patients are very limited.
- This study aims to evaluate the pharmacokinetics and effectiveness of ustekinumab after the induction period through a prospective multi - center cohort study.

### Method overview:
- Include Crohn's disease patients aged 2 - 17 years in the Canadian Paediatric IBD Network.
- Patients receive ustekinumab intravenous injection (IV) and actively measure the serum UST level at week 8.
- Compare the UST levels of children with body weight < 40 kg and ≥40 kg at week 8 and subsequent time points.
- Calculate the "dose - exposure ratio", that is, the induction dose divided by the blood drug level at week 8.
- Define clinical remission as wPCDAI < 12.5.
- Use the ROC curve to determine the optimal UST level at week 8 related to clinical remission at week 16 and the subsequent continued use of UST.

### Conclusions:
- Paediatric CD patients with body weight < 40 kg need a higher UST dose to achieve a drug exposure level comparable to that of patients with body weight ≥40 kg.
- A higher UST blood drug level is associated with a better clinical outcome, and the optimal UST level range at week 8 is 6 - 8 μg/mL.

Through this study, the researchers hope to optimize the medication regimen of ustekinumab in paediatric Crohn's disease patients, thereby improving the treatment effect and the long - term prognosis of patients.